| The Role of Inosine-5'-Monophosphate Dehydrogenase in Thiopurine Metabolism in Patients With Inflammatory Bowel Disease. | |
| | |
MedLine Citation:
|
PMID: 21311411 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND:: There is a large interindividual variability in thiopurine metabolism. High concentrations of methylthioinosine-5'-monophosphate (meTIMP) and low concentrations of 6-thioguanine nucleotides (6-TGNs) have been associated with a lower response rate and an increased risk of adverse events. In this study, the role of inosine-5'-monophosphate dehydrogenase (IMPDH) for differences in metabolite patterns of thiopurines was investigated. METHODS:: IMPDH activity and thiopurine metabolite concentrations were determined in patients with inflammatory bowel disease and a normal thiopurine methyltransferase (TPMT) phenotype and meTIMP/6-TGN concentration ratio > 20 (n = 26), in patients with a metabolite ratio ≤20 (n = 21), in a subgroup with a metabolite ratio <4 (n = 6), and in 10 patients with reduced TPMT activity. In vitro studies were conducted on human embryonic kidney cells (HEK293) with genetically engineered IMPDH and TPMT activities. RESULTS:: Patients with metabolite ratios >20 had lower IMPDH activity than those with ratios ≤20 (P < 0.001). Metabolic ratios >20 were only observed in patients with normal TPMT activity. Downregulation of IMPDH activity in HEK293 cells was associated with an increase in the concentration of meTIMP (fold change: 17 up to 93, P < 0.001) but, unexpectedly, also of 6-thioguanosine monophosphate (fold change: 2.6 up to 5.0, P < 0.001). CONCLUSIONS:: These data question the general view of IMPDH as the rate-limiting enzyme in the phosphorylation of thiopurines. Investigations of other mechanisms are needed to more fully explain the various metabolite patterns and outcomes in patients under treatment. |
| | |
Authors:
|
Sofie Haglund; Svante Vikingsson; Jan Söderman; Ulf Hindorf; Christer Grännö; Margareta Danelius; Sally Coulthard; Curt Peterson; Sven Almer |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-2-09 |
Journal Detail:
|
Title: Therapeutic drug monitoring Volume: - ISSN: 1536-3694 ISO Abbreviation: - Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-2-11 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7909660 Medline TA: Ther Drug Monit Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
From the *Division of Gastroenterology and Hepatology, Department of Experimental and Clinical Medicine, Linköping University, Linköping; †Division of Medical Diagnostics, Laboratory Medicine, Ryhov Hospital, Jönköping; ‡Division of Drug Research, Department of Medicine and Health, Linköping University, Linköping; §Department of Gastroenterology, Lund University Hospital, Lund; ¶Department of Medicine, Ryhov Hospital, Jönköping; ∥Department of Internal Medicine, Ersta Hospital, Stockholm, Sweden; and **Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association of Genetic Polymorphisms in the Influx Transporter SLCO1B3 and the Efflux Transporter AB...
Next Document: Interleukin-13 protects mouse intestine from ischemia and reperfusion injury through regulation of i...